IP2, an immunomodulatory agent, enhances PTP (Pioneer Translation Product)-derived antigen presentation in cancer cells without exhibiting cytotoxicity. Additionally, IP2 has been shown to induce tumor growth defects in mouse models [1].

IP2 (35 µM) exhibits immunomodulatory activity in murine MCA205 fibrosarcoma cells [1].

IP2 demonstrates high bioavailability in mice at dosage levels of 0.711 mg/kg intraperitoneally (i.p.) and 9.103 mg/kg intravenously (i.v.), and in dogs at 26.76 mg/kg i.v. [1]. When administered i.p. to C57BL/6 mice at a range of 50 to 500 mg/kg, IP2 is well-tolerated [1]. Furthermore, at 2.5 mg/kg i.v. and 5 mg/kg via direct intratumoral injection thrice weekly for two weeks, IP2 significantly inhibits tumor growth in C57BL/6 mice [1]. Pharmacokinetic parameters for IP2 in male C57BL/6J mice and male beagle dogs reveal the following: intraperitoneally administered to mice, IP2 has a maximal concentration (C max) of 2078 ng/mL, time to reach maximum concentration (T max) of 0.0833 hours, half-life (T 1/2) of 0.8 hours, clearance (CL) of 154 mL/min/kg, bioavailability (F) of 86%, mean residence time from 0 to time t (MRT 0-t) of 0.7 hours, and area under the curve (AUC) tot of 982.3 ng/mL·h with extraparent percent (AUC extra) of 1.3%. When administered intravenously to mice, the corresponding values are a C max of 322.7 ng/mL, T max of 0.0833 hours, T 1/2 of 1.1 hours, CL of 133 mL/min/kg, F of 0.9%, MRT 0-t of 88.8 hours, AUC tot of 15.2 ng/mL·h. In dogs, the compound shows a C max of 272 µg/mL, T max of 0.0833 hours, T 1/2 of 3.8 hours, CL of 0.69 mL/min/kg, F of 3.8%, MRT 0-t of 654.7 µg/mL·h, and AUC extra of 0.9% [1].